Overview

Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors

Status:
RECRUITING
Trial end date:
2027-10-14
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, exploratory clinical study to evaluate the safety, tolerability and preliminary efficacy of Anti-Mesothelin CAR-T cell injection in patients with Mesothelin-positive advanced malignant solid tumors.
Phase:
NA
Details
Lead Sponsor:
Zhejiang University
Collaborator:
UTC Therapeutics Inc.
Treatments:
Cyclophosphamide
fludarabine